Anastrozole is a nonsteroidal aromatase inhibitor (AI) commonly used as adjuvant therapy for postsurgical treatment of estrogen receptor–positive breast cancer. Although ocular adverse effects of tamoxifen (a selective estrogen receptor modulator) are well described, only a few studies1-4 have identified retinal hemorrhages, optic disk swelling, vitreoretinal traction, and dry eye as ocular adverse effects of AIs. This case report describes a patient with documented uveitis and cystoid macular edema (CME) during AI treatment.
Sathiamoorthi S, Ruddy KJ, Bakri SJ. Association of Uveitis and Macular Edema With Anastrozole Therapy. JAMA Ophthalmol. 2018;136(7):837–839. doi:10.1001/jamaophthalmol.2018.1700
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: